[ad_1] OSLO, Norway, Dec. 8, 2025 /PRNewswire/ — Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of a health economics abstract from the BRAVO study at the Society of Urologic Oncology 2025 […]
Tag: Photocure
New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison
[ad_1] OSLO, Norway, Dec. 8, 2025 /PRNewswire/ — Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of a health economics abstract from the BRAVO study at the Society of Urologic Oncology 2025 […]
New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management
[ad_1] OSLO, Norway , Nov. 19, 2025 /PRNewswire/ — Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study “Hexaminolevulinate-enhanced photodynamic diagnosis in the management of non-muscle-invasive bladder cancer (NMIBC): The […]
Results for the third quarter of 2025
[ad_1] OSLO, Norway, Oct. 29, 2025 /PRNewswire/ — Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 134.1 million in the third quarter of 2025 (Q3 2024: NOK 120.1 million), and an EBITDA of NOK […]
Results for the third quarter of 2025
[ad_1] OSLO, Norway, Oct. 29, 2025 /PRNewswire/ — Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 134.1 million in the third quarter of 2025 (Q3 2024: NOK 120.1 million), and an EBITDA of NOK […]
